Imatinib in pulmonary arterial hypertension: c-Kit inhibition

Pulmonary Circulation

Volumn 4, Issue 3, 2014, Pages 452-455

  Farha, Samar ^a,b   Dweik, Raed ^a,b   Rahaghi, Franck ^c   Benza, Raymond ^d   Hassoun, Paul ^e   Frantz, Robert ^f   Torres, Fernando ^g   Quinn, Deborah A ^h   Comhair, Suzy ^b   Erzurum, Serpil ^a,b   Asosingh, Kewal ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c DEPARTMENT OF COLORECTAL SURGERY   (United States)

^d ALLEGHENY GENERAL HOSPITAL   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

c Kit; Imatinib; Mast cells; Progenitor cells; Pulmonary hypertension

Indexed keywords

EID: 85026339584     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/677359     Document Type: Article

References (14)

1. Ogawa M, Matsuzaki Y, Nishikawa S, et al. Expression and function of c-kit in hemopoietic progenitor cells. T Exp Med 1991;174:63-71.
2. Montani D, Perros F, Gambaryan N, et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am T Respir Crit Care Med 2011;184: 116-123.
3. Gambaryan N, Perros F, Montani D, et al. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir T 2011;37:1392-1399.
4. Gambaryan N, Perros F, Montani D, Cohen-Kaminsky S, Mazmanian GM, Humbert M. Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. Eur Respir T 2010;36:1209-1211.
5. Banasova A, Maxova H, Hampl V, et al. Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia. Respiration 2008;76:102-107.
6. Farha S, Sharp T, Asosingh K, et al. Mast cell number, phe-notype, and function in human pulmonary arterial hypertension. Pulm Circ 2012;2:220-228.
7. Rastogi P, White MC, Rickard A, McHowat J. Potential mechanism for recruitment and migration of CD133 positive cells to areas of vascular inflammation. Thromb Res 2008;123:258-266.
8. Radinger M, Tensen BM, Kuehn HS, Kirshenbaum A, Gilfillan AM. Generation, isolation, and maintenance of human mast cells and mast cell lines derived from peripheral blood or cord blood. Curr Protoc Immunol 2010:7.3712-3717.
9. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13). Blood 1999;94:2333-2342.
10. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl T Med 2005;353:1412-1413.
11. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006;145: 152-153.
12. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am T Respir Crit Care Med 2010;182:1171-1177.
13. Hoeper MM, Barst RT, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127:1128-1138.
14. Farha S, Asosingh K, Xu W, et al. Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood 2011;117:3485-3493.